Myositis Response Criteria at week 24 by Total Improvement Score category (intent-to-treat analysis population). DM, dermatomyositis; IMNM, immune-mediated necrotizing myopathy; PM, polymyositis
Phase III trial evaluated subcutaneous abatacept + standard of care (SOC) for idiopathic inflammatory myopathy
Over 24 wks, abatacept+SOC failed to show improved efficacy over placebo; however, patients with non-DM subtypes appeared to have sustained benefit up to 1 year
A&R
acr.tw/3ARxyMs
#Medsky
